A processing trial incorporates a diverse range of cancer patients, including melanoma, NSCLC, RCC, and bladder cancer candidates, employing defined bacteria strains (MRx0518) together with regular anti-PD1 ICI therapy, expecting to observe clinical efficacy (71). This evidence concerns the gene PDCD1 and renal cell carcinoma.